Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges

被引：8
|
作者：
Ravi, Praful [1 ]
Whelpley, Bridget [1 ]
Kelly, Emma [1 ]
Wolanski, Andrew [1 ,2 ]
Ritzer, Jolivette [1 ,2 ]
Robertson, Matthew [1 ,2 ]
Shah, Hina [1 ,2 ]
Morgans, Alicia K. [1 ]
Wei, Xiao X. [1 ]
Sunkara, Rajitha [1 ]
Pomerantz, Mark [1 ]
Taplin, Mary -Ellen [1 ]
Kilbridge, Kerry L. [1 ]
Choudhury, Atish D. [1 ]
Jacene, Heather [1 ,2 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Boston, MA USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2023年 / 64卷 / 03期
关键词：
RESISTANT PROSTATE-CANCER; MULTICENTER; THERAPY;
D O I：
10.2967/jnumed.122.265194
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：349 / 350
页数：2
相关论文
共 50 条
  • [41] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [42] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [43] Cocktail Therapy of 177Lu-PSMA-617 and 177Lu-EDTMP in Patients With mCRPC A Proof-of-Principle Application
    Bal, Chandrasekhar
    Yadav, Madhav Prasad
    Ballal, Sanjana
    CLINICAL NUCLEAR MEDICINE, 2016, 41 (08) : E386 - E387
  • [44] OP-338First-in-Human Study of 177Lu-EB-PSMA-617 in patients with MetastaticCastration-Resistant Prostate Cancer and Comparison with 177Lu-PSMA-617
    Zang, J.
    Wang, H.
    Liu, Q.
    Wang, J.
    Jacobson, O.
    Niu, G.
    Zhu, Z.
    Chen, X.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S111 - S111
  • [45] Preclinical dosimetric studies of 177Lu-scFvD2B and comparison with 177Lu-PSMA-617 and 177Lu-iPSMA endoradiotherapeutic agents
    Melendez-Alafort, Laura
    Ferro-Flores, Guillermina
    Santos-Cuevas, Clara
    Ocampo-Garcia, Blanca
    Turato, Sofia
    Fracasso, Giulio
    Bolzati, Cristina
    Rosato, Antonio
    De Nardo, Laura
    MEDICAL PHYSICS, 2021, 48 (07) : 4064 - 4074
  • [46] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [47] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Mader, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
  • [48] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [49] Treatment of liver metastases of castration resistant prostate cancer with 177Lu-PSMA-617 and SIRT
    Seifert, Robert
    Boegemann, Martin
    Kahler, Michael
    Dittmann, Matthias
    Weckesser, Matthias
    Rahbar, Kambiz
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [50] Risk and Concomitant Factors of Renal Insufficiency throughout Radioligand Treatment with 177Lu-PSMA-617
    Ngoc, C. Nguyen
    Mader, N.
    Davis, K.
    Groener, D.
    Happel, C.
    Mandel, P.
    Tselis, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S490 - S490
12345